“Bausch Health is off to a strong start in 2019 with the continued growth of XIFAXAN which grew 11% in the quarter, the launch of BRYHALI, the successful acquisition of TRULANCE, and the approval of DUOBRII and expected launch in June. We believe that our promising pipeline and focus on Project CORE has positioned the company to build on our growth in 2019 and beyond. Strong operational execution is leading us to raise our full-year 2019 revenue and adjusted EBITDA guidance,” said Joseph Papa, chairman and CEO, Bausch Health. “With nearly 60% of our revenues coming from a diversified mix of medical devices, OTC products and prescription and branded generic products that are not exposed to the U.S. branded prescription drug pricing environment, we believe that Bausch Health is uniquely positioned to grow in health care,” Papa continued.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.